References
Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA (2016) Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin 6:12–18
Witzens M, Moehler T, Neben K, Fruehauf S, Hartschuh W, Ho AD, Goldschmidt H (2004) Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Ann Hematol 83(7):467–470
Osório RM, Pina S, Salero T, Coelho MV, Sousa D, Mendonça C (2020) Association of multiple myeloma and giant cell arteritis - a case report. Eur J Case Rep Intern Med 7(1):001360
Keung YK, Yung C, Wong JW, Shah F, Cobos E (1998) Association of temporal arteritis, retinal vasculitis, and xanthomatosis with multiple myeloma: case report and literature review. Mayo Clin Proc 73(7):657–660
Estrada A, Stenzel TT, Burchette JL, Allen NB (1998) Multiple myeloma-associated amyloidosis and giant cell arteritis. Arthritis Rheum 41(7):1312–1317
Slart RHJA, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees, SNMMI Cardiovascular, Members of Council, PET Interest Group, Members of ASNC, EANM Committee Coordinator (2018) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 45(7):1250–1269
Benfaremo D, Gabrielli A (2019) Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases? Cells 9(1):77
Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T (2020) Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 383(12):1149–1155
Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1(1):31–35
Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A (2020) Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 20(8):509–518
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics
The patient provided informed consent for this publication. The General Hospital of Šibenik-Knin County, Croatia, does not require ethical approval for reporting individual cases or case series.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Krečak, I., Ruščić, I., Zlatović, J.J. et al. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone. Ann Hematol 100, 1623–1624 (2021). https://doi.org/10.1007/s00277-020-04369-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-04369-9